Since 2017, an incredible 16 CAR-T cell therapies have reached commercialization, with several more nearing the finish line. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other major markets as well. These include:
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- Carvykti (ciltacabtagene autoleucel)
- Aucatzyl (obecabtagene autoleucel)
Beyond the U.S., six CAR-T therapies (Carteyva, Yikaida, Yorwida, Zevor-cel, Fucaso, and Satri-cel) have been approved by China’s National Medical Products Administration (NMPA), including Satri-cel, which made history this year as the world’s first CAR-T cell therapy approved for a solid tumor. [Read more…]
